SavedAdd your journal

Journals / European Journal of Biology / 2023 / Volume: 82 Issue: 2

Oxidative Stress and Cancer: Harnessing the Therapeutic Potential of Curcumin and Analogues Against Cancer

Christoffer Lambring(University of North Texas Health Science Center)0009-0003-2921-5021
Liling Chen(University of North Texas Health Science Center)0009-0006-0191-1887
Claire Nelson(Missouri Southern State University)0009-0008-9256-4634
Alyssa Stevens(Missouri Southern State University)0009-0005-6799-0090
Wynashia Bratcher(Livingstone College)0009-0004-2385-6685
Riyaz Basha(University of North Texas Health Science)0000-0002-4071-0993
Pages
—
Publication Date
2023-12-21
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review highlights ROS function in cancer treatment focused on ROS, including Curcumin and its analogs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Reactive oxygen species (ROS) are a class of bioactive molecules that are the by-products of many cellular functions.
📊
Key Findings & Data:These molecules are present in normal cells at homeostatic levels but have been studied extensively in cancer due to their dysregulation resulting in pro- and anti-tumorigenic environments.
💡
Conclusion & Impact:This review highlights ROS function in cancer treatment focused on ROS, including Curcumin and its analogs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Oxidative Stress · Curcumin · Curcumin analogs

Abstract

Reactive oxygen species (ROS) are a class of bioactive molecules that are the by-products of many cellular functions. These molecules are present in normal cells at homeostatic levels but have been studied extensively in cancer due to their dysregulation resulting in pro- and anti-tumorigenic environments. Completely understanding the paradoxical nature of ROS in cancer is imperative to fully realize its modulation as cancer therapy. Studies into ROS have shown far-reaching effects in cancer, including how ROS levels regulate signaling, response to treatment, drug resistance, etc. Many drugs were studied with the hopes of regulating the ROS levels in cancer; however, patient response varied. Plant-derived medications offered new avenues of drug treatment over the last few decades, and the phytochemical Curcumin gained ground as an interesting cancer therapeutic. Curcumin is an active phenolic compound used in traditional medicine around the world. Although it suffers from a poor pharmacokinetic profile, Curcumin exerts anti-tumorigenic, as well as ROS-modulating activities. Analogs and derivatives of Curcumin are under development to improve upon its anti-cancer properties and enhance its bioavailability, currently a major limitation of its usage. This review highlights ROS function in cancer treatment focused on ROS, including Curcumin and its analogs.

🔖

Cite This Article

Lambring, C., Chen, L., Nelson, C., Stevens, A., Bratcher, W., Basha, R. (2023). Oxidative Stress and Cancer: Harnessing the Therapeutic Potential of Curcumin and Analogues Against Cancer. European Journal of Biology, Volume: 82 Issue: 2. https://doi.org/10.26650/EurJBiol.2023.1348427

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (75)

  1. Sahoo BM, Banik BK, Borah P, Jain A. Reactive oxygen species (ROS): Key components in cancer therapies. Anticancer Agents Med Chem. 2022;22(2):215-222. google scholar
  2. Reczek CR, Chandel NS. ROS Promotes cancer cell survival through calcium signaling. Cancer Cell. 2018;33(6):949-951. google scholar
  3. Schafer ZT, Grassian AR, Song L, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 2009;461(7260):109-113. google scholar
  4. Weinberg F, Ramnath N, Nagrath D. Reactive oxygen species in the tumor microenvironment: An overview. Cancers (Basel). 2019;11(8). doi:10.3390/cancers11081191 google scholar
  5. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931-947. google scholar
  6. Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron trans-port chain, ROS generation and uncoupling (Review). Int J Mol Med. 2019;44(1):3-15. google scholar
  7. Perillo B, Di Donato M, Pezone A, et al. ROS in cancer therapy: The bright side of the moon. Exp Mol Med. 2020;52(2):192-203. google scholar
  8. Sena LA, Chandel NS. Physiological roles of mitochondrial re-active oxygen species. Mol Cell. 2012;48(2):158-167. google scholar
  9. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J. 1996;313 (Pt 1)(Pt 1):17-29. google scholar
  10. Okon IS, Zou MH. Mitochondrial ROS and cancer drug resis-tance: Implications for therapy. Pharmacol Res. 2015;100:170-174. google scholar
  11. Nakamura H, Takada K. Reactive oxygen species in can-cer: Current findings and future directions. Cancer Sci. 2021;112(10):3945-3952. google scholar
  12. Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU. Oxidative stress and its role in cancer. J Cancer Res Ther. 2021;17(1):22-28. google scholar
  13. Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387-400. google scholar
  14. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolu-tion. Genes Cells. 2011;16(2):123-140. google scholar
  15. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregula-tion in cancer. Redox Biol. 2013;1(1):45-49. google scholar
  16. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401-426. google scholar
  17. Li W, Kong AN. Molecular mechanisms of Nrf2-mediated an-tioxidant response. Mol Carcinog. 2009;48(2):91-104. google scholar
  18. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. google scholar
  19. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077-3080. doi:10.1158/0008-5472.CAN-07-3293 google scholar
  20. Hanahan D, Weinberg RA. Hallmarks of cancer: The next gener-ation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013 google scholar
  21. Arihara Y, Takada K, Kamihara Y, et al. Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma. Oncotarget. 2017;8(39):65889-65899. google scholar
  22. Nakamura H, Takada K, Arihara Y, et al. Six-transmembrane epithelial antigen of the prostate 1 protects against increased ox-idative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer. Cancer Gene Ther. 2019;26(9-10):313-322. google scholar
  23. Shiau JP, Chuang YT, Cheng YB, et al. Impacts of oxida-tive stress and PI3K/AKT/mTOR on metabolism and the fu-ture direction of investigating fucoidan-modulated metabolism. Antioxidants (Basel). 2022;11(5). doi:10.3390/antiox11050911 google scholar
  24. Wen C, Wang H, Wu X, et al. ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin. Cell Death Dis. 2019;10(11):809. doi:10.1038/s41419-019-2035-x google scholar
  25. Wang Y, Qi H, Liu Y, et al. The double-edged roles of ROS in cancer prevention and therapy. Theranostics. 2021;11(10):4839-4857. google scholar
  26. Assi M. The differential role of reactive oxygen species in early and late stages of cancer. Am J Physiol Regul Integr Comp Physiol. 2017;313(6):R646-R653. google scholar
  27. Zalewska-Ziob M, Adamek B, Kasperczyk J, et al. Activity of antioxidant enzymes in the tumor and adjacent noncancerous tissues of non-small-cell lung cancer. Oxid Med Cell Longev. 2019;2901840. doi:10.1155/2019/2901840 google scholar
  28. Reczek CR CN. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol. 2017;1:79-98. google scholar
  29. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837. google scholar
  30. Li Y, Zhang X, Wang Z, Li B, Zhu H. Modulation of redox homeostasis: A strategy to overcome cancer drug resistance. Front Pharmacol. 2023;14:1156538. doi:10.3389/fphar.2023.1156538 google scholar
  31. Aggarwal V, Tuli HS, Varol A, et al. Role of reactive oxygen species in cancer progression: Molecular mecha-nisms and recent advancements. Biomolecules. 2019;9(11). doi:10.3390/biom9110735 google scholar
  32. Yu G, Sun W, Shen Y, et al. PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis. Am J Transl Res. 2018;10(6):1793-1801. google scholar
  33. Huang W, Zeng YC. A candidate for lung cancer treatment: arsenic trioxide. Clin Transl Oncol. 2019;21(9):1115-1126. google scholar
  34. Massaro RR, Faiao-Flores F, Rebecca VW, et al. Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. Pharmacol Res. 2017;119:242-250. google scholar
  35. Karlsson JO, Kurz T, Flechsig S, Nasstrom J, Andersson RG. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct. Transl Oncol. 2012;5(6):492-502. google scholar
  36. Coriat R, Alexandre J, Nicco C, et al. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest. 2014;124(1):262-272. google scholar
  37. Wang J, Ren XR, Piao H, et al. Niclosamide-induced Wnt sig-naling inhibition in colorectal cancer is mediated by autophagy. Biochem J. 2019;476(3):535-546. google scholar
  38. Disoma C, Zhou Y, Li S, Peng J, Xia Z. Wnt/beta-catenin signal-ing in colorectal cancer: Is therapeutic targeting even possible? Biochimie. 2022;195:39-53. google scholar
  39. Lotfi N, Yousefi Z, Golabi M, et al. The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update. Front Immunol. 2023;14:1077531. doi:10.3389/fimmu.2023.1077531 google scholar
  40. Shafer D, Tombes MB, Shrader E, et al. Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma. Neurooncol Adv. 2020;2(1):vdz052. doi:10.1093/noajnl/vdz052 google scholar
  41. Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. J Nutr. 2019;149(7):1133-1139. google scholar
  42. Talib WH, Alsalahat I, Daoud S, Abutayeh RF, Mahmod AI. Plant-derived natural products in cancer research: extraction, mecha-nism of action, and drug formulation. Molecules. 2020;25(22). doi:10.3390/molecules25225319 google scholar
  43. Hashem S, Ali TA, Akhtar S, et al. Targeting cancer sig-naling pathways by natural products: Exploring promising anti-cancer agents. Biomed Pharmacother. 2022;150:113054. doi:10.1016/j.biopha.2022.113054 google scholar
  44. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631-1652. google scholar
  45. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclin-ical studies to clinical practice. Front Pharmacol. 2019;10:1614. doi:10.3389/fphar.2019.01614 google scholar
  46. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem. 1995;270(42):24995-5000. google scholar
  47. Marin YE, Wall BA, Wang S, et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res. 2007;17(5):274-283. google scholar
  48. Paul S, Sa G. Curcumin as an adjuvant to cancer immunotherapy. Front Oncol. 2021;11:675923. doi:10.3389/fonc.2021.675923 google scholar
  49. Kim GY, Kim KH, Lee SH, et al. Curcumin inhibits immunostim-ulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol. 2005;174(12):8116-8124. google scholar
  50. Giordano A, Tommonaro G. Curcumin and cancer. Nutrients. 2019;11(10). doi:10.3390/nu11102376 google scholar
  51. Wang H, Zhang K, Liu J, et al. Curcumin regulates cancer pro-gression: Focus on ncRNAs and molecular signaling pathways. Front Oncol. 2021;11:660712. doi:10.3389/fonc.2021.660712 google scholar
  52. Sadatsharifi M, Purgel M. Radical scavenger competition of alizarin and curcumin: A mechanistic DFT study on antioxidant activity. J Mol Model. 2021;27(6):166. doi:10.1007/s00894-021-04778-1 google scholar
  53. Jakubczyk K, Druzga A, Katarzyna J, Skonieczna-Zydecka K. Antioxidant Potential of curcumin-a meta-analysis of randomized clinical trials. Antioxidants (Basel). 2020;9(11). doi:10.3390/antiox9111092 google scholar
  54. Wang T, Wu X, Al Rudaisat M, Song Y, Cheng H. Cur-cumin induces G2/M arrest and triggers autophagy, ROS gen-eration and cell senescence in cervical cancer cells. J Cancer. 2020;11(22):6704-6715. google scholar
  55. Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato JY. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018;8(1):2039. doi:10.1038/s41598-018-20179-6 google scholar
  56. Liu C, Rokavec M, Huang Z, Hermeking H. Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis. Cell Death Differ. 2023;30(7):1771-1785. google scholar
  57. Gabr SA, Elsaed WM, Eladl MA, et al. Curcumin modulates oxidative stress, fibrosis, and apoptosis in drug-resistant cancer cell lines. Life (Basel). 2022;12(9). doi:10.3390/life12091427 google scholar
  58. Wang G, Duan P, Wei Z, Liu F. Curcumin sensitizes carbo-platin treatment in triple negative breast cancer through reac-tive oxygen species induced DNA repair pathway. Mol Biol Rep. 2022;49(4):3259-3270. google scholar
  59. Wu MF, Huang YH, Chiu LY, Cherng SH, Sheu GT, Yang TY. Curcumin induces apoptosis of chemoresistant lung cancer cells via ROS-Regulated p38 MAPK phosphorylation. Int J Mol Sci. 2022;23(15). doi:10.3390/ijms23158248 google scholar
  60. Dairam A, Limson JL, Watkins GM, Antunes E, Daya S. Curcum-inoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats. J Agric Food Chem. 2007;55(3):1039-1044. google scholar
  61. Ravindran J, Subbaraju GV, Ramani MV, Sung B, Aggar-wal BB. Bisdemethylcurcumin and structurally related his-polon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. Biochem Pharmacol. 2010;79(11):1658-1666. google scholar
  62. Mbese Z, Khwaza V, Aderibigbe BA. Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast can-cers. Molecules. 2019;24(23). doi:10.3390/molecules24234386 google scholar
  63. Nakamae I, Morimoto T, Shima H, et al. Curcumin derivatives verify the essentiality of ROS upregulation in tumor suppression.Molecules. 2019;24(22). doi:10.3390/molecules24224067 google scholar
  64. Wang H, Xu Y, Sun J, Sui Z. The novel curcumin derivative 1g induces mitochondrial and ER-stress-dependent apoptosis in colon cancer cells by induction of ROS production. Front Oncol. 2021;11:644197. doi:10.3389/fonc.2021.644197 google scholar
  65. Liu X, Cui H, Li M, et al. Tumor killing by a dietary curcumin mono-carbonyl analog that works as a selective ROS genera-tor via TrxR inhibition. Eur J Med Chem. 2023;250:115191. doi:10.1016/j.ejmech.2023.115191 google scholar
  66. Chen M, Qian C, Jin B, et al. Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma. Cancer Biol Ther. 2023;24(1):2162807. doi:10.1080/15384047.2022.2162807 google scholar
  67. Feng C, Xia Y, Zou P, et al. Curcumin analog L48H37 induces apoptosis through ROS-mediated endoplasmic reticulum stress and STAT3 pathways in human lung cancer cells. Mol Carcinog. 2017;56(7):1765-1777. google scholar
  68. Rajamanickam V, Yan T, Wu L, et al. Allylated curcumin analog CA6 inhibits TrxR1 and leads to ROS-dependent apoptotic cell death in gastric cancer through Akt-FoxO3a. Cancer Manag Res. 2020;12:247-263. google scholar
  69. Zhang Z, Lin R, Liu Z, et al. Curcumin analog, WZ37, pro-motes G2/M arrest and apoptosis of HNSCC cells through Akt/mTOR inhibition. Toxicol In Vitro. 2020;65:104754. doi:10.1016/j.tiv.2019.104754 google scholar
  70. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm. 2007;4(6):807-818. google scholar
  71. Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2014;66(1):222-307. google scholar
  72. Lao CD, Ruffin MTt, Normolle D, et al. Dose escalation of a cur-cuminoid formulation. BMC Complement Altern Med. 2006;6:10. doi:10.1186/1472-6882-6-10 google scholar
  73. Sandhiutami NMD, Arozal W, Louisa M, Rahmat D, Wuyung PE. Curcumin nanoparticle enhances the anticancer effect of cisplatin by inhibiting PI3K/AKT and JAK/STAT3 pathway in rat ovarian carcinoma induced by DMBA. Front Pharmacol. 2020;11:603235. doi:10.3389/fphar.2020.603235 google scholar
  74. Adahoun MA, Al-Akhras MH, Jaafar MS, Bououdina M. En-hanced anti-cancer and antimicrobial activities of curcumin nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45(1):98-107. google scholar
  75. Basniwal RK, Khosla R, Jain N. Improving the anticancer ac-tivity of curcumin using nanocurcumin dispersion in water. Nutr Cancer. 2014;66(6):1015-1022. google scholar